{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:16:10Z","timestamp":1788621370730,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s13730-021-00645-3","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T06:26:39Z","timestamp":1631687199000},"page":"171-176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Nivolumab-induced membranous nephropathy in a patient with stage IV lung adenocarcinoma"],"prefix":"10.1007","volume":"11","author":[{"given":"Keiko","family":"Wakabayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoko","family":"Okawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumie","family":"Teramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Kusunoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3813-9484","authenticated-orcid":false,"given":"Masanobu","family":"Takeji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,15]]},"reference":[{"key":"645_CR1","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.urolonc.2017.08.005","volume":"35","author":"AW Hahn","year":"2017","unstructured":"Hahn AW, Gill DM, Agarwal N, Maughan BL. PD-1 checkpoint inhibition: toxicities and management. Urol Oncol. 2017;35:701.","journal-title":"Urol Oncol"},{"issue":"1","key":"645_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"645_CR3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.currproblcancer.2016.12.004","volume":"41","author":"N Murakami","year":"2017","unstructured":"Murakami N, Motwani S, Riella LV. Renal complications of immune checkpoint blockade. Curr Probl Cancer. 2017;41(2):100\u201310.","journal-title":"Curr Probl Cancer"},{"issue":"7","key":"645_CR4","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785\u201392.","journal-title":"J Clin Oncol"},{"issue":"2","key":"645_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"key":"645_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ekir.2020.10.002","volume":"6","author":"A Kitchlu","year":"2020","unstructured":"Kitchlu A, Jhaveri KD, Wadhwani S, Deshpande P, Harel Z, Kishibe T, et al. Immune checkpoint inhibitor-associated glomerular disease: a systematic review and descriptive analysis. Kidney Int Rep. 2020;6:66.","journal-title":"Kidney Int Rep"},{"key":"645_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001287","author":"JS Lin","year":"2020","unstructured":"Lin JS, Wang DY, Mamlouk O, Glass WF, Abdelrahim M, Yee C, et al. Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-001287.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"645_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","volume":"7","author":"O Mamlouk","year":"2019","unstructured":"Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer. 2019;7(1):2.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"645_CR9","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2169\/internalmedicine.9814-17","volume":"57","author":"S Kishi","year":"2018","unstructured":"Kishi S, Minato M, Saijo A, Murakami N, Tamaki M, Matsuura M, et al. IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma. Intern Med. 2018;57(9):1259\u201363.","journal-title":"Intern Med"},{"key":"645_CR10","first-page":"2638283","volume":"2020","author":"J Cruz-Whitley","year":"2020","unstructured":"Cruz-Whitley J, Giehl N, Jen KY, Young B. Membranoproliferative glomerulonephritis associated with nivolumab therapy. Case Rep Nephrol. 2020;2020:2638283.","journal-title":"Case Rep Nephrol"},{"issue":"2","key":"645_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMc0904283","volume":"361","author":"F Fadel","year":"2009","unstructured":"Fadel F, Karoui KE, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med. 2009;361(2):211\u20132.","journal-title":"N Engl J Med"},{"key":"645_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ekir.2018.10.017","volume":"4","author":"T Ashour","year":"2019","unstructured":"Ashour T, Nakhoul G, Patil P, Funchain P, Herlitz L. Immune check point inhibitor-associated glomerulonephritis. Kidney Int Rep. 2019;4:355\u20139.","journal-title":"Kidney Int Rep"},{"issue":"6","key":"645_CR13","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1053\/j.ajkd.2019.04.016","volume":"74","author":"AJ Gallan","year":"2019","unstructured":"Gallan AJ, Alexander E, Reid P, Kutuby F, Chang A, Henriksen KJ. Renal vasculitis and pauci-immune glomerulonephritis associated with immune checkpoint inhibitors. Am J Kidney Dis. 2019;74(6):853\u20136.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"645_CR14","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1016\/j.jtho.2017.03.011","volume":"12","author":"MH Heo","year":"2017","unstructured":"Heo MH, Kim HK, Lee H, Ahn M-J. Antineutrophil cytoplasmic antibody-associated rapid progressive glomerulonephritis after pembrolizumab treatment in thymic epithelial tumor: a case report. J Thorac Oncol. 2017;12(8):e103\u20135.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"645_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12882-016-0408-2","volume":"17","author":"K Jung","year":"2016","unstructured":"Jung K, Zeng X, Bilusic M. Nivolumab-associated acute glomerulonephritis: a case report and literature review. BMC Nephrol. 2016;17(1):188.","journal-title":"BMC Nephrol"},{"issue":"9","key":"645_CR16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/CJI.0000000000000189","volume":"40","author":"RA Daanen","year":"2017","unstructured":"Daanen RA, Maas RJ, Koornstra RH, Steenbergen EJ, van Herpen CM, Willemsen AE. Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma. J Immunother. 2017;40(9):345\u20138.","journal-title":"J Immunother"},{"issue":"1","key":"645_CR17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12882-018-0958-6","volume":"19","author":"B Gao","year":"2018","unstructured":"Gao B, Lin N, Wang S, Wang Y. Minimal change disease associated with anti-PD1 immunotherapy: a case report. BMC Nephrol. 2018;19(1):156.","journal-title":"BMC Nephrol"},{"issue":"4","key":"645_CR18","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1053\/j.ajkd.2017.04.026","volume":"70","author":"A Kitchlu","year":"2017","unstructured":"Kitchlu A, Fingrut W, Avila-Casado C, Chan CT, Crump M, Hogg D, et al. Nephrotic syndrome with cancer immunotherapies: a report of 2 cases. Am J Kidney Dis. 2017;70(4):581\u20135.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"645_CR19","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.kint.2015.11.028","volume":"89","author":"JM Kidd","year":"2016","unstructured":"Kidd JM, Gizaw AB. Ipilimumab-associated minimal-change disease. Kidney Int. 2016;89(3):720.","journal-title":"Kidney Int"},{"key":"645_CR20","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1186\/s12885-016-2718-y","volume":"16","author":"A Bickel","year":"2016","unstructured":"Bickel A, Koneth I, Enzler-Tschudy A, Neuweiler J, Flatz L, Fruh M. Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. BMC Cancer. 2016;16:656.","journal-title":"BMC Cancer"},{"key":"645_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejca.2019.11.011","volume":"125","author":"S Ville","year":"2020","unstructured":"Ville S, Kandel-Aznar C, Fr\u00e9meaux-Bacchi V, Fakhouri F. C3 glomerulonephritis in a patient treated with anti\u2013PD-1 antibody. Eur J Cancer. 2020;125:46\u20138.","journal-title":"Eur J Cancer"},{"issue":"1","key":"645_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000364782","volume":"40","author":"N Leeaphorn","year":"2014","unstructured":"Leeaphorn N, Kue APP, Thamcharoen N, Ungprasert P, Stokes MB, Knight EL. Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies. Am J Nephrol. 2014;40(1):29\u201335.","journal-title":"Am J Nephrol"},{"issue":"8","key":"645_CR23","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1038\/sj.ki.5001790","volume":"70","author":"C Lefaucheur","year":"2006","unstructured":"Lefaucheur C, Stengel B, Nochy D, Martel P, Hill GS, Jacquot C, et al. Membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association. Kidney Int. 2006;70(8):1510\u20137.","journal-title":"Kidney Int"},{"issue":"2","key":"645_CR24","first-page":"241","volume":"7","author":"A Aytekin","year":"2017","unstructured":"Aytekin A, Ozet A, Bilgetekin I, Ogut B, Ciltas A, Benekli M. A case of membranous glomerulopathy associated with lung cancer and review of the literature. Mol Clin Oncol. 2017;7(2):241\u20133.","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"645_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck Jr","year":"2009","unstructured":"Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"4","key":"645_CR26","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/ckj\/sfv049","volume":"8","author":"J Lonnbro-Widgren","year":"2015","unstructured":"Lonnbro-Widgren J, Ebefors K, Molne J, Nystrom J, Haraldsson B. Glomerular IgG subclasses in idiopathic and malignancy-associated membranous nephropathy. Clin Kidney J. 2015;8(4):433\u20139.","journal-title":"Clin Kidney J"},{"issue":"5","key":"645_CR27","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1093\/ndt\/gfr534","volume":"27","author":"Z Qu","year":"2012","unstructured":"Qu Z, Liu G, Li J, Wu LH, Tan Y, Zheng X, et al. Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. Nephrol Dial Transplant. 2012;27(5):1931\u20137.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"645_CR28","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1093\/ndt\/gfg616","volume":"19","author":"H Ohtani","year":"2004","unstructured":"Ohtani H, Wakui H, Komatsuda A, Okuyama S, Masai R, Maki N, et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant. 2004;19(3):574\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"645_CR29","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.semnephrol.2010.09.011","volume":"30","author":"H Laurence","year":"2010","unstructured":"Laurence H, Beck J. Membranous nephropathy and malignancy. Semin Nephrol. 2010;30(6):635\u201344.","journal-title":"Semin Nephrol"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-021-00645-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-021-00645-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-021-00645-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T13:19:09Z","timestamp":1651497549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-021-00645-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["645"],"URL":"https:\/\/doi.org\/10.1007\/s13730-021-00645-3","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,15]]},"assertion":[{"value":"26 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have declared that no Conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent was obtained from the individual.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}